{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:46:08Z","timestamp":1778154368559,"version":"3.51.4"},"reference-count":21,"publisher":"Walter de Gruyter GmbH","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The purpose of this study was to investigate when in pregnancy to stop the administration of low dose aspirin (150 mg\/daily) so as to prevent fetal growth restriction (FGR) A randomised, placebo-controlled study was designed. The patients were all screened positive using the Fetal Medicine Foundation (FMF) early pregnancy screening test for preeclampsia (PE) and FGR prediction. One hundred and fifty patients were enrolled and divided equally into three groups: A \u2013 the controls who received placebo treatment; B \u2013 those who received aspirin till 32 weeks of gestation and C \u2013 those who received aspirin till 36 weeks of gestation. The mean gestational age at enrollment was similar for all the groups (12.4 weeks). The growth curves, fetal and maternal Doppler measurements and amniotic fluid index (AFI) were monitored every 4 weeks. Also, the outcome of the pregnancy was noted and all the results were compared between the groups. FGR was defined as a fetal weight below the 10<jats:sup>th<\/jats:sup> centile for gestational age. In group C, there were less cases of FGR compared with the other groups: 6% vs. 10% in group B vs. 24% in controls. Also, there was a significant birth weight improvement in this group with a median of 3180 g compared with 2950 g in group B and 2760 g in group A (P=0.01). The gestational age at delivery was similar in all the groups (39 weeks in group C\/39.2 weeks in group B\/38.6 weeks in group A). In conclusion, low dose aspirin improves the outcome in the selected population and should be offered for prevention of FGR from 12 to 36 weeks.<\/jats:p>","DOI":"10.1515\/jpm-2017-0184","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T10:01:34Z","timestamp":1517306494000},"page":"776-779","source":"Crossref","is-referenced-by-count":18,"title":["Low dose aspirin for preventing fetal growth restriction: a randomised trial"],"prefix":"10.1515","volume":"46","author":[{"given":"Anca-Daniela","family":"Stanescu","sequence":"first","affiliation":[{"name":"Saint John Hospital, Bucur Maternity , University of Medicine and Pharmacy Carol Davila , Bucharest , Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Banica","sequence":"additional","affiliation":[{"name":"Medicover Hospital , Bucharest , Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina-Marina","family":"Sima","sequence":"additional","affiliation":[{"name":"Saint John Hospital, Bucur Maternity , University of Medicine and Pharmacy Carol Davila , Bucharest , Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana","family":"Ples","sequence":"additional","affiliation":[{"name":"Saint John Hospital, Bucur Maternity , University of Medicine and Pharmacy Carol Davila , Bucharest , Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"2021021318314463629_j_jpm-2017-0184_ref_001_w2aab3b7c35b1b6b1ab2b1b1Aa","unstructured":"NICE Clinical Guideline. National Collaborating Centre for Women\u2019s and Children\u2019s Health. Commissioned by the National Institute for Health and Clinical Excellence. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. CG107. http:\/\/guidance.nice.org.uk\/CG107."},{"key":"2021021318314463629_j_jpm-2017-0184_ref_002_w2aab3b7c35b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Lowe SA, Brown MA, Dekker GA, Gatt S, McLintock CK, McMahon LP, et al. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust N Z J Obstet Gynaecol. 2009;49:242\u20136.","DOI":"10.1111\/j.1479-828X.2009.01003.x"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_003_w2aab3b7c35b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Pijnenborg R, Dixon G, Robertson WB, Brosens I. Trophoblastic invasion of human decidua from 8 to 18 weeks of pregnancy. Placenta. 1980;1:3\u201319.","DOI":"10.1016\/S0143-4004(80)80012-9"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_004_w2aab3b7c35b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Brosens I, Pijnenborg R, Vercruysse L, Romero R. The \u201cgreat obstetrical syndromes\u201d are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011;204:193\u2013201.","DOI":"10.1016\/j.ajog.2010.08.009"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_005_w2aab3b7c35b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Roberge S, Nicolaides KH, Demers S, Villa P, Bujold E. Prevention of perinatal death and adverse outcome using low dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol. 2013;41:491\u20139.","DOI":"10.1002\/uog.12421"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_006_w2aab3b7c35b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116(2 Pt 1):402\u201314.","DOI":"10.1097\/AOG.0b013e3181e9322a"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_007_w2aab3b7c35b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Bujold E, Roberge S, Nicolaides KH. Low dose-aspirin for prevention of adverse outcomes related to abnormal placentation. Prenat Diagn. 2014;34:642\u20138.","DOI":"10.1002\/pd.4403"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_008_w2aab3b7c35b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Hermida RC, Ayala DE, Iglesias M, Moj\u00f3n A, Silva I, Ucieda R, et al. Time-dependent effects of low dose aspirin administration on blood pressure in pregnant women. Hypertension. 1997;30(3 Pt 2):589\u201395.","DOI":"10.1161\/01.HYP.30.3.589"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_009_w2aab3b7c35b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int. 2013;30:260\u201379.","DOI":"10.3109\/07420528.2012.717455"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_010_w2aab3b7c35b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Hermida RC, Ayala DE, Fernandez JR, Moj\u00f3n A, Alonso I, Silva I, et al. Administration time-dependent effects of aspirin in women at differing risk for preeclampsia. Hypertension. 1999;34(4 Pt 2):1016\u201323.","DOI":"10.1161\/01.HYP.34.4.1016"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_011_w2aab3b7c35b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S. Aspirin and congenital malformations. Lancet. 1976;i:1373\u20135.","DOI":"10.1016\/S0140-6736(76)93025-7"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_012_w2aab3b7c35b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med. 1989;321:1639\u201342.","DOI":"10.1056\/NEJM198912143212404"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_013_w2aab3b7c35b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Norgard B, Puho E, Czeizel AE, Skriver MV, S\u00f8rensen HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol. 2005;192:922\u20133.","DOI":"10.1016\/j.ajog.2004.10.598"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_014_w2aab3b7c35b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Turan O, Block-Abraham D, Doyle L, Kopelman J, Atlas R, Jenkins C, et al. Starting aspirin (ASA) in the first trimester (T1) promotes placental invasion in low-risk pregnancy. 34th Annual Meeting of the Society for Maternal-Fetal Medicine The Pregnancy Meeting; 2014; New Orleans, Louisiana.","DOI":"10.1016\/j.ajog.2013.10.317"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_015_w2aab3b7c35b1b6b1ab2b1c15Aa","unstructured":"Sibai BM, Mirro R, Chesney CM, Leffler C. Low-dose aspirin in pregnancy. Obstet Gynecol. 1989;74:551\u20137."},{"key":"2021021318314463629_j_jpm-2017-0184_ref_016_w2aab3b7c35b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Schiessl B, Schneider KT, Zimmermann A, Kainer F, Friese K, Oberhoffer R. Prenatal constriction of the fetal ductus arteriosus--related to maternal pain medication? Z Geburtshilfe Neonatol. 2005;209:65\u20138.","DOI":"10.1055\/s-2005-864116"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_017_w2aab3b7c35b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Wyatt-Ashmead J. Antenatal closure of the ductus arteriosus and hydrops fetalis. Pediatr Dev Pathol. 2011;14:469\u201374.","DOI":"10.2350\/07-11-0368.1"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_018_w2aab3b7c35b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Di Sessa TG, Moretti ML, Khoury A, Pulliam DA, Arheart KL, Sibai BM. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol. 1994;171:892\u2013900.","DOI":"10.1016\/S0002-9378(94)70056-7"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_019_w2aab3b7c35b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Leonhardt A, Bernert S, Watzer B, Schmitz-Ziegler G, Seyberth HW. Low-dose aspirin in pregnancy: maternal and neonatal aspirin concentrations and neonatal prostanoid formation. Pediatrics. 2003;111:e77\u201381.","DOI":"10.1542\/peds.111.1.e77"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_020_w2aab3b7c35b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Bleyer WA, Breckenridge RT. Studies on the detection of adverse drug reactions in the newborn. II. The effects of prenatal aspirin on newborn hemostasis. J Am Med Assoc. 1970;213:2049\u201353.","DOI":"10.1001\/jama.1970.03170380023004"},{"key":"2021021318314463629_j_jpm-2017-0184_ref_021_w2aab3b7c35b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007;18:CD004659.","DOI":"10.1002\/14651858.CD004659.pub2"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jpme.2018.46.issue-7\/jpm-2017-0184\/jpm-2017-0184.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2017-0184\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2017-0184\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T01:34:57Z","timestamp":1619055297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2017-0184\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,1,30]]},"published-print":{"date-parts":[[2018,9,25]]}},"alternative-id":["10.1515\/jpm-2017-0184"],"URL":"https:\/\/doi.org\/10.1515\/jpm-2017-0184","relation":{},"ISSN":["1619-3997","0300-5577"],"issn-type":[{"value":"1619-3997","type":"electronic"},{"value":"0300-5577","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1,30]]}}}